Anti–Glomerular Basement Membrane (Anti-GBM) Disease Insights and Trends

• Anti-GBM disease is a rare and rapidly progressive autoimmune disorder caused by circulating autoantibodies directed against the glomerular and alveolar basement membranes, leading to severe kidney and lung injury.
• Anti-GBM disease is rare, with only about 1 in 1 million new cases being reported per year. 
• Anti–GBM disease is a small-vessel vasculitis involving the kidneys (∼90%) and the lungs (∼60%). 
• Increasing use of anti-GBM antibody testing, kidney biopsy with linear IgG deposition, and advanced renal diagnostic techniques has improved diagnostic accuracy and early disease detection, although delayed diagnosis remains common due to the rarity and rapid progression of the disease.
• Anti-GBM disease is an ultra-rare autoimmune vasculitis disorder, with an estimated incidence of approximately 0.5–1.8 cases per million population annually, contributing to substantial morbidity, mortality, and healthcare burden despite its low prevalence.
• Anti-GBM disease is an ultra-rare autoimmune vasculitic disorder with an estimated annual incidence of approximately 0.5–1.8 cases per million population, making it one of the rarest forms of rapidly progressive glomerulonephritis.
• The disease demonstrates a characteristic bimodal age distribution, with one peak occurring in young adults and a second peak in older individuals, while younger patients are more likely to present with pulmonary involvement. 

Anti–Glomerular Basement Membrane (Anti-GBM) Disease Epidemiology Forecast in the 7MM

• 2025 Diagnosed Incident Cases of Anti-GBM Disease: ~XX
• 2036 Projected Diagnosed Prevalent Cases of Anti-GBM Disease: ~XXX
• Anti-GBM Disease  Growth Rate (2026–2036): ~XX% CAGR

DelveInsight's ‘Anti–Glomerular Basement Membrane (Anti-GBM) Disease Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the Anti-GBM Disease, historical and forecasted epidemiology, in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Anti–Glomerular Basement Membrane (Anti-GBM) Disease Understanding

Anti–Glomerular Basement Membrane (Anti-GBM) Disease Overview

Anti–glomerular basement membrane (Anti-GBM) disease, also known as Goodpasture’s syndrome, is a rare and rapidly progressive autoimmune disorder characterized by circulating autoantibodies targeting the glomerular and alveolar basement membranes, primarily affecting the kidneys and lungs. The disease commonly presents with rapidly progressive glomerulonephritis (RPGN), hematuria, proteinuria, acute kidney injury, and in some patients, pulmonary hemorrhage with respiratory distress. Delayed treatment may lead to end-stage renal disease (ESRD) and significant mortality. 

Further details are provided in the report.

Anti–Glomerular Basement Membrane (Anti-GBM) Disease Diagnosis

Diagnosis of anti-GBM disease is primarily based on clinical evaluation, serologic testing, and kidney biopsy findings. Detection of circulating anti-GBM antibodies using enzyme-linked immunosorbent assay (ELISA) remains the key diagnostic test, while kidney biopsy demonstrating linear IgG deposition along the glomerular basement membrane by immunofluorescence is considered the diagnostic hallmark. Additional laboratory investigations, including serum creatinine, urinalysis, proteinuria assessment, and inflammatory markers, help evaluate renal involvement and disease severity. Imaging studies such as chest X-ray or CT scan may be performed in patients with suspected pulmonary hemorrhage or lung involvement. 

Further details are provided in the report.

Anti–Glomerular Basement Membrane (Anti-GBM) Disease Epidemiology

Key Findings from Anti–Glomerular Basement Membrane (Anti-GBM) Disease Epidemiological Analysis and Forecast 

• Anti-GBM Disease is an extremely rare but serious small vessel vasculitis and its incidence is approximately 0.5–1.8 cases per million population per year. 
• Given its rarity, definitive observations regarding the incidence of Anti-GBM disease are lacking. It is often said to have an incidence of about 1 per million population per year in European populations, largely on the basis of single-center biopsy- or serology-based series, although accurately defining populations at risk in such studies is difficult. 
• Anti-GBM disease has a bimodal age distribution, with peaks in the third decade (slight male preponderance) and in the sixth to seventh decades (no gender difference) and the disease in the elderly appears to take a milder course.
• Annual incidence ranged from 0.4 to 2.8 per million population per year and the average incidence over the observation period was 1.64 per million population per year. 
• Anti-GBM disease most often affects men in their 20s and women in their 60s, but it can occur at any age. The condition can occur in children, but this is extremely rare. 
• The highest proportion of anti-GBM disease cases occurs in females aged 30–49 years (50%), followed by those aged 49–65 years (40%), while females aged over 65 years account for 10% of cases. 
• The incidence of anti-GBM disease is about 1–1.64 per million population per year.
• Anti-GBM disease has a double peak in age incidence, one in the second-third decade and one in the sixth-seventh decade. In children, 0.4% of all causes of CKD are reported to be due to anti-GBM disease.

Scope of the Report

• The report covers a segment of a descriptive overview of Anti-GBM Disease, explaining their causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression. 

Report Insights

Anti-GBM Disease Patient Population Forecast

Report Key Strengths

• Epidemiology‑based (Epi‑based) Bottom‑up Forecasting
• 11-year Forecast 
• Patient Burden Trends (by geography)

FAQs

• What are the disease risks, burdens, and unmet needs of Anti-GBM disease? What will be the growth opportunities across the 7MM concerning the patient population with Anti-GBM disease?
• What is the historical and forecasted Anti-GBM Disease patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.